article
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
List view / Grid view
In Vitro
article
In vitro platforms for de-risking nephrotoxicity during drug development
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
article
Pooling research and development resources to tackle emerging threats
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
article
Assays In-Depth Focus 2020
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
article
Drug Target Review – Issue 1 2020
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
news
Innate protein restricts HIV replication by targeting lipid rafts
According to a new study, apolipoprotein A-I binding protein restricts HIV-1 replication by targeting lipid rafts and reducing virus-cell fusion.
news
Organoids produced to help develop paediatric brain tumour treatments
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
news
Stem cell models of human spine development unveiled
Scientists have created the first lab-dish models of the cellular clock, where each 'tick' stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue.
article
Exploring chemical space for epigenetic drug discovery using AI
It is said that, on average, it takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way. Can artificial intelligence (AI) help to speed things up? Sheraz Gul and Alp Sahin provide an overview of an AI approach…
article
Expert view: Following mitchondrial substrate oxidation pathways to expose novel drug targets
Energy metabolism drives everything we do, so it is no surprise that the more we discover about these metabolic processes, the more we observe seamless integration with all core cellular functions.
news
Function of protein involved in liver cancer discovered
The involvement of clathrin in the development of liver cancer has been described for the first time, which could lead to more targeted therapy.
news
Protective antibody discovery could lead to better flu treatments
Researchers have identified a set of three antibodies that they suggest could become the basis for a new antiviral treatment and inform the development of new influenza vaccines.
whitepaper
Application note: Evaluate anti-inflammatory compounds using a multiparametric THP-1 cell-based assay
Macrophages originate from blood monocytes that leave the circulation and penetrate various tissues where they differentiate into macrophages. They are involved in the removal of pathogens and phagocytosis of dead cells. In addition, they initiate inflammation by releasing cytokines that activate vascular cells and facilitate macrophage adhesion to blood vessels…
news
Anticancer activity delivered by targeting mitochondrial cell regulator
Disruption of the MFF-VDAC1 complex could lead to a potential therapeutic target for cancer.
news
In vitro toxicology and toxicity testing market to exhibit CAGR of 9.3 percent
The worldwide market for in vitro toxicology and toxicity testing is predicted to be worth $12.7 billion by the end of the forecast period.
